Cisplatin + nintedanib + pemetrexed + placebo
WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ... WebPemetrexed (Alimta) is administered as 500 mg/m 2 as an intravenous infusion over 10 minutes after pembrolizumab and prior to carboplatin or cisplatin on day 1 of each 21-day cycle for 4 cycles for initial treatment of metastatic non-squamous NSCLC in individuals with a creatinine clearance of 45 mL/min or greater.
Cisplatin + nintedanib + pemetrexed + placebo
Did you know?
WebGültigkeitsbereich: Leitlinie Tumorzentrum Oberösterreich Bronchuskarzinom Paz-Ares L, Gridelli C et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer (PARAMOUNT): a double-blind ... WebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ...
WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … WebThis study enrolled 87 participants with chemo-naïve unresectable MPM, ECOG performance status 0–1, and non-sarcomatoid disease histology. Patients were randomized 1:1, double blinded, to cisplatin/pemetrexed with nintedanib 200 mg b.d. or placebo, and nintedanib or placebo was subsequently continued as monotherapy until progression.
WebJul 24, 2013 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … WebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may …
WebPatients were randomly assigned in a 1:1 ratio to receive nintedanib or placebo. Randomization was stratified by histology (epithelioid or biphasic). Treatment with …
WebSep 18, 2024 · This study aims to evaluate the safety of nintedanib when used in combination with pemetrexed and cisplatin in patients with unresectable MPM. This randomized, double-blind, placebo-controlled, phase 3 trial included a total of 458 patients with unresectable epithelioid MPM. can lispro be mixedWebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME … can lispro and regular insulin be mixedWebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … can lispro be mixed with nphWebApr 7, 2024 · This is a Phase II trial assessing the efficacy of nintedanib, an oral multi-targeted kinase inhibitor, in patients with recurrent malignant pleural mesothelioma. The drug was well tolerated but the activity was modest with no responses and 40% stable disease at 8 weeks. can lispro and nph be mixed in same syringeWebNov 1, 2024 · This concept was based on the following reasoning: pemetrexed plus cisplatin is a standard first-line regimen in MPM; a phase III trial in advanced MPM confirmed that treatment with pemetrexed as a second-line regimen resulted in improved progression-free survival (PFS) over best supportive care. 5 In a Dutch single-arm … fix bent wheels near meWebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. … canlis phone numberWebNintedanib is an oral angiokinase inhibitor targeting multiple signaling pathways implicated in the pathogenesis of MPM, including the VEGF receptor. The phase III part of the … fix bernzomatic igniter